Abstract 1857P
Background
The COVID-19 pandemic has been closely associated with a decline in mental health. The goal of this study was to identify the degree of distress of cancer patients before and after the pandemic and to find out if COVID-19 worsened the mental health of cancer patients.
Methods
A self-rated survey was conducted for 2 groups of patients at The Todua Clinic, Tbilisi, Georgia twice: at the peak of pandemic and again 6 months after the pandemic. Study included adult cancer patients, with solid tumors, over 18 years of age, receiving chemotherapy, being able to understand and answer the questions in written English. Event Scale-Revised (IES-R) test was implemented to measure Post-Traumatic Stress Disorder (PTSD). Total IES-R score of 33 or over signifies the likely presence of PTSD.
Results
Study enrolled total of 195 patients, 103 patients - during and 92 - after the pandemic. 3 independent and 5 dependent variables were created. Independent variables were: 1. IES-R score ≥24 ( y=1 if score ≥ 24, y=0 if score ≤ 24); 2. IES-R score≥ 33 (y=1 if score ≥ 33, y=0 if score ≤ 33); 3. IES-R score 37 (y= 1 if score ≤ 37, y=0 f score ≤ 37). Five dependent variables were: time, type of disease, stage, sex, and marital status. We created 3 regression models with independent and dependent variables (model 1: independent variable was IES-R score ≥24, model 2 independent variable was - IES-R score ≥ 33, model 3 IES-R score ≥ 33). We observed improvement in IES-R scores in the post-pandemic period: In model 1 - results improved by 20%, In model 2 - 16%, and in model 3 – 14%. Female and married individuals had better results in both periods. We calculated the data and observed that all dependent variables other than the disease type and the disease stage had a significant impact on IES-R scores.
Conclusions
Our findings showed a significant difference in IES-R scores in patients before and after the COVID-19 pandemic, with notable improvement in the post-COVID period. We also observed that sex, disease stage, marital status, and disease stage affected IES-R scores. We conclude that COVID-19 worsened the mental health of cancer patients. Our study highlighted the need for efforts to better integrate psychosocial support into cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05